anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: ALK-4290
Trial phase: Phase 2
SMILES: Cc1cc(C(=O)N(C)C)cc(NC(=O)[C@H]2CCC(=O)N2C2CCN(Cc3ccc(Cl)c(C)c3)CC2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: Subjects will receive AKST4290, 400 mg twice daily, for 12 weeks.

AKST4290: Oral AKST4290
Eligibility criteria:
Key Inclusion Criteria:

Diagnosis of clinically established or clinically probable PD according to MDS-PD criteria with at least 1 year of PD symptoms.
Modified Hoehn and Yahr ≤2.5.
Have notable motor worsening during off-medication state.
Clear-cut improvement of motor response to levodopa medications, as assessed by the investigator.
Must be on stable dopaminergic therapy (e.g., levodopa, dopamine agonists, monoamine oxidase inhibitors, catechol-O-methyl transferase inhibitors, amantadine), for at least 8 weeks prior to enrollment and remain on stable dose during the 12-week treatment period.
Female subjects must not be pregnant or breastfeeding. Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening. WOCBP must agree to use highly effective contraception prior to study entry. Male subjects must be willing to use a barrier method of contraception.

Key Exclusion Criteria:

Secondary or atypical parkinsonian syndromes, for example, patients with parkinsonism from encephalitis, metabolic disorders, vascular parkinsonism, drug-induced parkinsonism, multiple system atrophy, corticobasal ganglia degeneration, progressive supranuclear palsy, Lewy body dementia.
History of any brain surgery for PD (e.g., pallidotomy, deep brain stimulation, or fetal tissue transplant).
Conditions affecting the peripheral or central nervous system, unless related to PD, that would affect the ability to adequately perform the MDS-UPDRS and motor assessments: i.e., severe sensory neuropathy affecting arm or leg function, or stroke affecting motor or gait function.
Significant alcohol or drug abuse within past 2 years.
Based on ECG reading, subjects with a risk of QT prolongation.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Iron
Trial phase: Phase 3
ATC code: A11AA01 | B03AE01 | B03AE02 | B03AE03 | B03AE04
SMILES: [Fe]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 1
Group description: Arm A is standard oral iron therapy for 3 months.

Ferrous Sulfate: Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
Eligibility criteria:
Inclusion Criteria:

Age greater than or equal to 12 months to less than 48 months

Iron deficiency anemia (IDA) confirmed by hematologic indices and iron laboratory parameters*

Hgb between greater than or equal to 6 g/dL AND less than or equal to 10 g/dL
MCV less than or equal to 70 fl
Ferritin less than or equal to 15 ng/mL OR TIBC greater than or equal to 425 microgram/dL *CBC indices must be performed with 7 days of study enrollment. Iron indices must be performed within 30 days of study enrollment.
Clinical history consistent with nutritional IDA such as prolonged breastfeeding without adequate iron supplementation or excessive milk intake (cow milk, almond milk, soy milk, goat milk or other milk, excluding breastmilk), defined as greater than or equal to 3 cups (24 ounces)per day
Primary language of English or Spanish
Access to smartphone with data plan and/or other internet access (i.e. home computer)

Exclusion Criteria:

Iron deficiency likely or definitely due to blood loss from the intestine or other sites.
Administration of a blood transfusion
History or evidence of intestinal malabsorption
History of prior intravenous iron therapy
Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination, or laboratory tests
Other cause of anemia (sickle cell disease, thalassemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests.
Inability to tolerate oral medications
Other medical or social factors at discretion of treating physician
Intervention: Ciclesonide
Trial phase: Phase 3
ATC code: R01AD13 | R03BA08
SMILES: [H][C@@]12C[C@@]3([H])O[C@@H](C4CCCCC4)O[C@@]3(C(=O)COC(=O)C(C)C)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 197
Group description: Participants receive Alvesco 320mcg, twice daily for 30 days via pMDI

Ciclesonide: 160mcg Inhaler
Eligibility criteria:
Inclusion Criteria

Patients eligible for enrollment in the study must meet all the following criteria:

Male and female adults and adolescents (12 years of age and above).
Positive SARS-CoV-2 rapid molecular diagnostic test within 72 hours prior to enrollment.
Patient is not currently hospitalized or under immediate consideration for hospitalization at the time of enrollment.
Patient is currently experiencing symptoms of fever, cough, and/or dyspnea.
Patient has an oxygen saturation level greater than 93%.
Ability to show adequate use of MDI, including inhalation technique.
Patient, parent/legal guardian, or legally-authorized representative must have signed a written informed consent before administration of any study-specific procedures.

Exclusion Criteria

Patients meeting any of the following criteria are not eligible for participation in the study:

Existence of any life-threatening co-morbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion.
History of hypersensitivity to ciclesonide.
Treatment with inhaled or intranasal corticosteroids within 14 days of the screening/ enrollment/randomization visit.
Treatment with oral corticosteroids within 90 days of the screening/enrollment/randomization visit.
Participation in any other clinical trial or use of any investigational agent within 30 days of the screening/enrollment/randomization visit.
Currently receiving treatment with hydroxychloroquine/chloroquine.
Patients with cystic fibrosis.
Patients with idiopathic pulmonary fibrosis.
Intervention: Docusate
Trial phase: Phase 2
SMILES: CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 154
Group description: Docusate sodium one pill to was taken twice a day by mouth for 28 days

Docusate Sodium: Patients in the docusate sodium arm received the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days.
Eligibility criteria:
Inclusion Criteria:

Admission to Cleveland Clinic Lutheran Hospital surgical unit 5D
Single total knee replacement surgery by orthopedic surgeons Stearns, Murray, or Molloy
Age greater than 20
Discharge to home on postoperative day one

Exclusion Criteria:

Known allergy to PEG 3350
Unable to complete a follow up phone call in English
Known renal disease, irritable bowel syndrome, or inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Intervention: PROPYLENE GLYCOL
Trial phase: Phase 2
SMILES: CC(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 154
Group description: One standard dose (17 grams) of propylene glycol by mouth on postoperative day one

Propylene Glycol: Patients in the propylene glycol arm received one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery.
Eligibility criteria:
Inclusion Criteria:

Admission to Cleveland Clinic Lutheran Hospital surgical unit 5D
Single total knee replacement surgery by orthopedic surgeons Stearns, Murray, or Molloy
Age greater than 20
Discharge to home on postoperative day one

Exclusion Criteria:

Known allergy to PEG 3350
Unable to complete a follow up phone call in English
Known renal disease, irritable bowel syndrome, or inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Dexamethasone ophthalmic insert 0.4 mg

Dexamethasone ophthalmic insert 0.4 mg: intracanalicular dexamethasone insert
Eligibility criteria:
Inclusion Criteria:

Age 18 years and older
Scheduled for bilateral SMILE surgery
Willing and able to comply with clinic visits and study related procedures
Willing and able to sign the informed consent form

Exclusion Criteria:

Patients under the age of 18.
Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
Active infectious systemic disease
Active infectious ocular or extraocular disease
Obstructed nasolacrimal duct in the study eye(s)
Hypersensitivity to dexamethasone
Patients being treated with immunomodulating agents in the study eye(s)
Patients being treated with immunosuppressants and/or oral steroids Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Intervention: PREDNISOLONE ACETATE
Trial phase: Phase 4
SMILES: CC(=O)OCC(=O)C1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3C(O)CC21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Topical prednisolone acetate ophthalmic drops per standard of care:

Every two hours on day of procedure, then four times a day for the first week, then two times a day for the second week, then discontinue.
Eligibility criteria:
Inclusion Criteria:

Age 18 years and older
Scheduled for bilateral SMILE surgery
Willing and able to comply with clinic visits and study related procedures
Willing and able to sign the informed consent form

Exclusion Criteria:

Patients under the age of 18.
Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
Active infectious systemic disease
Active infectious ocular or extraocular disease
Obstructed nasolacrimal duct in the study eye(s)
Hypersensitivity to dexamethasone
Patients being treated with immunomodulating agents in the study eye(s)
Patients being treated with immunosuppressants and/or oral steroids Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Intervention: Ifenprodil
Trial phase: Phase 2 | Phase 3
ATC code: C04AX28
SMILES: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: NP-120 (Ifenprodil) 20 mg TID + Standard of Care
Eligibility criteria:
Inclusion Criteria:

Male and female subjects aged ≥18 years of age

Confirmed coronavirus infection

Positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for COVID-19 nucleic acid
Viral gene sequences in respiratory or blood specimens that are highly homologous to COVID-19
Any other diagnostic test accepted by local regulatory authorities
Must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (Score of 4 or 5 on WHO Ordinal Clinical Scale)
Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s)
Non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s)
Subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

Exclusion Criteria:

Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline
Patients experiencing cerebral hemorrhage or cerebral infarction at baseline
ALT/AST > 5 times the upper limit of normal; Child-Pugh Score 10 to 15
Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
Patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Patients taking droxidopa
Pregnant and lactating women and those planning to get pregnant
Known or suspected allergy to the trial drug or the relevant drugs given in the trial
Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial
Know inability of patient to comply with the protocol for the duration of the study
Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. Participation in observational registry studies is permitted.
Intervention: Ifenprodil
Trial phase: Phase 2 | Phase 3
ATC code: C04AX28
SMILES: CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: NP-120 (Ifenprodil) 40 mg TID + Standard of Care
Eligibility criteria:
Inclusion Criteria:

Male and female subjects aged ≥18 years of age

Confirmed coronavirus infection

Positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for COVID-19 nucleic acid
Viral gene sequences in respiratory or blood specimens that are highly homologous to COVID-19
Any other diagnostic test accepted by local regulatory authorities
Must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (Score of 4 or 5 on WHO Ordinal Clinical Scale)
Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s)
Non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s)
Subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

Exclusion Criteria:

Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline
Patients experiencing cerebral hemorrhage or cerebral infarction at baseline
ALT/AST > 5 times the upper limit of normal; Child-Pugh Score 10 to 15
Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
Patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Patients taking droxidopa
Pregnant and lactating women and those planning to get pregnant
Known or suspected allergy to the trial drug or the relevant drugs given in the trial
Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial
Know inability of patient to comply with the protocol for the duration of the study
Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. Participation in observational registry studies is permitted.
Intervention: Sufentanil Citrate
Trial phase: Phase 4
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Participants in this arm will receive the intervention.

Sublingual Sufentanil: 15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
Eligibility criteria:
Inclusion Criteria:

- Adult patients undergoing outpatient ambulatory surgery undergoing general anesthesia for orthopedic surgery

Exclusion Criteria:

non-english speaking patients
patients who have allergy or intolerance to the study drugs or derivatives
Intervention: Cannabidiol
Trial phase: Phase 2 | Phase 3
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: Cannabidiol: The product is a liquid formulation that was prescribed at a dosage of 20 mg per day for a total of 3 days.
Eligibility criteria:
Inclusion Criteria:

Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen and pelvis) and who elect for definitive treatment via ureteroscopy at two sites within a tertiary care institution.
Age 18-75 years of age.
Patients of either gender.
Patients of all ethnic backgrounds.
Capable of giving informed consent.
Capable and willing to fulfill the requirements of the study.

Exclusion Criteria:

History of chronic pain.
Chronic use of opioid or other pain medication (> 12 weeks).
Known allergy to CBD oil or other cannabinoids.
Known or suspected pregnancy.
Inability to give informed consent or unable to meet requirements of the study for any reason.
Bilateral ureteroscopy.
Current marijuana, cannabidiol (CBD), or dronabinol use.
Liver disease/cirrhosis.
Current treatment of seizures with clobazam, valproate, or other antiepileptic medications.
Intervention: Nitric Oxide
Trial phase: Phase 2
ATC code: R07AX01
SMILES: [N]=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Will receive study drug treatment.

Nitric Oxide: Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization ("day 1"), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
Eligibility criteria:
Inclusion Criteria:

Age 18-85 years.
Admitted to the hospital (med-surg or critical care) with dyspnea

Diagnosis of COVID-19 based on either

positive nasal or oral pharyngeal swab by PCR, or
highly probable clinical picture based on clinical and CXR/CT scan
Requiring oxygen supplementation OR O2 saturation on room air of ≤ 94%

At least 2 of the following 4 risk factors for clinical worsening:

Age >= 60 years
T2DM or pre-diabetes as evidenced by either treatment with a hypoglycemic agent or any documented HgA1c >= 5.6
Obesity, based on BMI >= 30 kg/m2
Hypertension, based on treatment with an antihypertensive medication or systolic or diastolic blood pressure measurement >= 140 or >= 90 mmHg, documented at enrollment or at any time within the prior 6 months.

Exclusion Criteria:

Intubated or prior intubation (during present hospitalization) or anticipated intubation within the subsequent 2 hours.
Receiving > 5L/min flow nasal O2 to maintain O2sat greater than or equal to 92%
Using high-flow nasal cannula (HFNC) or non-invasive ventilation (NIV)
Receiving iNO, a PDE5 inhibitor, oral or intravenous nitrates, nitroprusside, prilocaine, sulfonamides, or riociguat.
Other major pulmonary, cardiac, such as chronic obstructive lung disease or heart failure, or systemic illness or disease involvement with potential to represent the primary driver for clinical deterioration within the next 3 days.
History of group 1 pulmonary hypertension.
Pregnancy
Active breast feeding
Severe chronic kidney disease, either receiving renal replacement therapy or eGFR < 15 ml/min/m2
Acute kidney injury (AKI), evidenced by acute doubling of serum creatinine within previous 48 hours.
Clinically relevant spontaneous alteration of mental state
Inability to provide written informed consent.
Intervention: Palmitic Acid
Trial phase: Phase 2
SMILES: CCCCCCCCCCCCCCCC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Lyophilized Lucinactant reconstituted with sterile water for injection

Lucinactant: Lucinactant administered as a liquid at a dose of 80 mg total phospholipids (TPL)/kg lean body weight delivered
Eligibility criteria:
Inclusion Criteria:

Signed and dated informed consent form (ICF) by the subject or legally authorized representative;
Age 18-75 (inclusive);
Assay positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, preferably by polymerase chain reaction (PCR);
Endotracheal intubation and mechanical ventilation (MV), within 7 days of initial intubation;
In-dwelling arterial line;
PaO2/FiO2 (P/F) ratio < 300;
Mean blood pressure ≥ 65 mmHg, immediately before enrollment;
Bilateral infiltrates seen on frontal chest radiograph.

Exclusion Criteria:

Life expectancy < 48 hours or do not resuscitate orders;
Severe lung disease (home O2, forced expiratory volume at one second [FEV1] < 2 liters) not likely to respond to therapy or profound hypoxemia (ie, oxygen index [OI] ≥ 25 or P/F ratio < 100);
Severe renal impairment (creatinine clearance < 30 mL/min);
Within the last 6 months has received, or is currently receiving, immunosuppression therapy (azathioprine, cyclophosphamide or methotrexate) or any transplant recipient;

Clinically significant cardiac disease that adversely effects cardiopulmonary function:

Acute coronary syndromes or active ischemic heart disease (as assessed by the PI using troponin and ECG)
Cardiac ejection fraction < 40% (if known);
Need for multiple-dose vasopressors to support blood pressure (single dose vasopressors, such as Levophed™ ≤ 0.1 mcg/kg/min are allowed);
Cardiogenic pulmonary edema as the etiology of the current respiratory distress;
Evidence of myocarditis or pericarditis;
Neuromuscular disease;
Neutropenia (ANC < 1000);
Active malignancy that impacts treatment decisions or life expectancy related to the trial;
Suspected concomitant bacterial or other viral lung infection. Bacterial infection defined as white blood count (WBC) > 15k and positive blood/urine/sputum culture results within 72 hours.
Intervention: Adenosine
Trial phase: Phase 3
ATC code: C01EB10 | J05AB03 | S01AD06
SMILES: Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush

Adenosine: A vial of adenosine with 6mg
Eligibility criteria:
Inclusion Criteria:

Svt
normal blood pressure
normal mentation
Give consent

Exclusion Criteria:

recent coffee
Allergy to adenosine
Asthma
cardiac operations